Advances in Frontline Management of Peripheral T-cell Lymphoma

Clin Lymphoma Myeloma Leuk. 2021 Jan 22:S2152-2650(21)00020-3. doi: 10.1016/j.clml.2021.01.012. Online ahead of print.ABSTRACTPeripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphomas that are frequently associated with a poor prognosis. For many decades, the standard-of-care has been CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-based therapy, but it is well-recognized that survival outcomes are unsatisfactory, especially when compared with B-cell lymphomas. Major recent advances in cancer diagnosis and management have the potential to significantly improve PTCL outcomes. These include: (1) improved diagnostic techniques that incorporate molecular genetic data to further refine diagnosis and subtyping; (2) the development of novel agents; and (3) improved monitoring modalities, such as 18F-fluorodeoxyglucose positron emission tomography-computed tomography scans and circulating tumor DNA. In this review, we aim to explore these 3 advances in the context of frontline management of PTCL.PMID:33610499 | DOI:10.1016/j.clml.2021.01.012

Source: Clinical Lymphoma and Myeloma - February 21, 2021 Category: Cancer & Oncology Authors: Chathuri Abeyakoon Carrie van der Weyden Sean Harrop Amit Khot Michael Dickinson Costas K Yannakou H Miles Prince Source Type: research